Cumberland Pharmaceuticals Inc.
2525 West End Avenue, Suite 950
Nashville, Tennessee 37203
Phone: (615) 255-0068
Toll Free: (877) 484-2700
Fax: (615) 255-0094
*For directions to us, please see Location
Phone: (877) 274-7200
Fax: (614) 652-9127
This website is not for medical emergencies. If you are a patient, caregiver or healthcare professional and need product related information, please visit our Products page, which will link you to product-specific websites.
Toll Free Phone: (866) 767-5077
(For healthcare professionals only)
A. GENERAL POLICY
The principles articulated herein are intended to provide guidance in the management of formal relationships between Cumberland Pharmaceuticals Inc. and its affiliates ("Cumberland") and their external constituencies in order to ensure that the design, conduct, and reporting of National Institutes of Health (NIH) and other externally funded research activities ("Sponsored Research") will not be biased by any conflicting financial interests. Under the Public Health Service (PHS) and National Science Foundation (NSF) final rules on Objectivity in Research (Federal Register, July 11, 1995), each investigator is required to disclose a listing of his/her significant financial interests, as well as those of his/her spouse and dependent children, that would reasonably appear to be affected by the research proposed for funding by the PHS or the NSF. If, after review of these disclosures, it is determined that the reported financial interests could directly and significantly affect the design, conduct, or reporting of the Sponsored Research, Cumberland will report the existence of such conflicting interests as required by the sponsor and act to protect the resulting research from bias owing to the conflict of interest. This policy statement is intended to satisfy current Federal rules for disclosure with regard to externally funded Sponsored Research where funds are provided by the NIH, PHS, NSF, as well as State of California statutes involving conflict of interest situations.
This policy and the associated procedures are applicable immediately to all Sponsored Research activities carried out by Cumberland employees, consultants, scientists, trainees, technicians and other agents of the research collaborators ("Cumberland associates"). The policy and the associated procedures are derived from the final rules on Objectivity in Research promulgated by the PHS and NSF that were published in the Federal Register of July 11, 1995 and the National Institute of Health (NIH) 2011 Revised Regulations on Financial Conflict of Interest. These procedures will be followed whenever Cumberland or its associates submit a request for funding from any external agency.
C. RESEARCH COMPLIANCE STATEMENT
The Compliance Statement for Cumberland:
It is Cumberland's responsibility to assure the integrity of all aspects of Sponsored Research while, simultaneously, taking care not to discourage the development of external funding opportunities. The purpose of this document is to identify situations where potential conflicts of significant financial interest are likely to arise and to establish a process whereby such conflicts are either avoided or at least managed equitably to the satisfaction of all concerned parties.
D. MANAGING CONFLICTS OF SIGNIFICANT FINANCIAL INTEREST
This document articulates Cumberland policy on the identification and management of significant financial conflicts of interest between outside constituencies and the associated Sponsored Research funding activities carried out by Cumberland. While this policy focuses upon identifying and managing conflicts of significant financial interest, its primary purpose is to promote compliance with the standards of Objectivity in Research.
A. CONFLICT OF SIGNIFICANT FINANCIAL INTEREST (CSFI):
CSFI is considered to occur whenever a Cumberland associate, or a family member of the associate, has an existing or potential financial or other material interest that impairs, or appears to impair, a Cumberland associate's independence and objectivity in the discharge of his/her responsibilities to and/or for Cumberland; or, alternatively, CSFI is considered to occur whenever a Cumberland associate receives financial or other material benefit through inappropriate use of knowledge or information confidential to Cumberland. It also refers to any SFI that could directly and significantly affect the design, conduct, or reporting of Sponsored Research.
B. CUMBERLAND ASSOCIATE:
Is any individual employed on a full- or part-time basis by Cumberland and is receiving, or will receive, compensation for such employment. This includes Consultants, Agents, and Research Collaborators of Cumberland.
Refers to the principal investigator, co-principal investigators, or any other Cumberland associate responsible for the design, conduct, or reporting of externally funded Sponsored Research activities.
D. FAMILY MEMBER:
This includes Cumberland associates' spouse and children or other adults who qualify as dependents under the Internal Revenue Code definitions.
Means any externally funded Sponsored Research activity conducted by Cumberland associates on behalf of the company
F. INVESTIGATOR'S COMPANY RESPONSIBILITIES
Refers to an investigator's professional responsibilities on behalf of Cumberland, and as defined by Cumberland in its policy on financial conflicts of interest, which may include for example: activities such as research, research consultation, teaching, professional practice, institutional committee memberships, and service panels such as Institutional Review Boards (IRB) or Data Safety Monitoring Boards (DSMB).
G. FINANCIAL INTEREST (FI):
Anything of monetary value, whether or not the value is readily ascertainable.
H. SIGNIFICANT FINANCIAL INTEREST (SFI)
A SFI exists when one or more of the following conditions exist with regard to interests of the investigator (and those of the investigator's spouse and dependent children) that reasonably appears to be related to the investigators' Cumberland responsibilities:
A. MANDATORY DISCLOSURE OF SIGNIFICANT FINANCIAL INTEREST:
In accord with relevant Federal and State of California regulations, Cumberland is required to identify and manage any potential conflicts of significant financial interests that may be inherent in the personal financial interest of an investigator involved in Sponsored Research. Cumberland, therefore, requires investigators to disclose to Cumberland, any significant financial interest, including those of his/her family members, which would reasonably appear to be affected by the project being funded by external government agencies.
Investigators participating in or proposed to participate in Sponsored Research are required to provide updated SFI disclosure information. Screening for SFIs will be conducted using Cumberland's SFI screening form at the time the application is submitted to the sponsor, before expenditure of any awarded funds or resources, and then annually during the award period for any Sponsored Research. Investigators shall promptly initiate disclosure to Cumberland after any change in reportable SFI disclosure information, according to the sponsor's time requirements.
B. IDENTIFICATION OF CONFLICTS OF SIGNIFICANT FINANCIAL INTEREST:
In conjunction with the administrative review of applications for Sponsored Research, Cumberland's Financial Disclosure Review Team (FDRT) will review each Financial Disclosure submitted and shall make a determination whether or not a CSFI exists. If the FDRT determines that no CSFI exists, the resulting negative findings will be filed in Cumberland's FDRT files. For negative findings, no further review is required.
In those instances where there are subrecipients under a prime award to Cumberland, the Research Subaward Agreement executed between Cumberland and each subrecipient organization will clarify which organization's SFI financial disclosure policy will apply to subrecipient investigators and subrecipient reporting requirements.
C. APPEAL OF POSITIVE FINDINGS:
Investigators may appeal a resulting positive finding to the FDRT leader for a review of the CSFI determination reached by the FDRT. The review of an appealed positive finding must be completed prior to the expenditure of any funds under an award. In reviewing positive findings, the FDRT leader will be guided and managed by the following principles: